Desmopressin_x0019_s role as a blood conservation agent in select patients undergoing cardiac surgery Emily Moose and Evan Tatum Novant Health Forsyth Medical Center - Winston-Salem, NC
Background/Purpose: Blood conservation strategies are implemented during cardiac surgery to decrease the potential short-term and long-term complications associated with blood transfusions. The objective of this study was to determine if there was a difference in transfusion requirements and Factor VIIa use between patients that receive desmopressin (DDAVP) and those that do not, that undergo cardiac surgery for aortic stenosis.
Methodology: This was a single-center, retrospective, case-control study approved by the Institutional Review Board. Adult patients undergoing cardiac surgery for aortic stenosis between June 1, 2016 and August 31, 2017 were included in the study. Patients were excluded for uremia, presence of von Willebrand disease or hemophilia A, existing or prior hyponatremia, contraindication or hypersensitivity to DDAVP, or if anticoagulation or antiplatelet therapies were not held appropriately prior to surgery. The treatment group received DDAVP 0.3 mcg/kg intravenously post-bypass during protamine administration. The treatment and control groups were randomly matched. In both arms, rates of acute renal failure, hyponatremia, transfusion requirements, and recombinant factor VIIa use were evaluated postoperatively.
Presentation Objective: Evaluate desmopressin_x0019_s role as a blood conservation agent in select patients undergoing cardiac surgery
Self-Assessment: What specific patient population would desmopressin provide potential benefit for in cardiac surgery?
